Business
Fifty1 Labs Partners with LUNR Aerospace to Pioneer AI-Driven Drug Repurposing for Space Medicine, Strategic Collaboration Aims to Harness AI and Orbital Access to Revolutionize Astronaut Health Solutions in a $2 Billion Market by 2032
VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 AI Labs, a subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), has entered a groundbreaking partnership with LUNR Aerospace to develop AI-driven drug repurposing initiatives tailored for space medicine. This collaboration targets critical health challenges in microgravity, including immune support, musculoskeletal resilience, neuro-ocular protection (Spaceflight-Associated Neuro-Ocular Syndrome, or SANS), cardiovascular
About this update from Fifty 1 Labs Inc.
[{"type":"image","alt":"Fifty 1 Labs, Inc.","displaySize":"","headline":null,"caption":"Fifty 1 Labs, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/e8c9e180126c109b22da024af95023de"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VXcgqPRzUayZ1jK6uTeZPA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e8c9e180126c109b22da024af95023de","width":300,"height":169}},"lazy":false},{"type":"text","content":"VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 AI Labs, a subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), has entered a groundbreaking partnership with LUNR Aerospace to develop AI-driven drug repurposing initiatives tailored for space medicine. This collaboration targets critical health challenges in microgravity, including immune support, musculoskeletal resilience, neuro-ocular protection (Spaceflight-Associated Neuro-Ocular Syndrome, or SANS), cardiovascular stability, cognitive performance, sleep optimization, and metabolic longevity, addressing the unique physiological demands of space exploration.","length":650,"tagName":"p"},{"type":"text","content":"The partnership launches a series of pilot programs to test AI-curated, repurposed therapeutics and nutraceuticals in space-relevant conditions, offering a cost-efficient and accelerated approach to innovation. This aligns with the rapidly expanding space medicine market, valued at USD 948.7 million in 2025 and projected to reach USD 1.97 billion by 2032, driven by an 11% compound annual growth rate (CAGR), according to Coherent Market Insights. The collaboration leverages Fifty1 Labs' expertise in AI-driven drug discovery and LUNR Aerospace's development of a cost-competitive delivery of research payloads to Low Earth Orbit and Sun-Synchronous Orbits, creating a robust ecosystem for space-based health innovation.","length":731,"tagName":"p"},{"type":"text","content":""Space exploration is pushing the boundaries of human endurance, and our partnership with LUNR Aerospace positions Fifty1 Labs at the forefront of ensuring astronaut health and performance in these extreme environments," said Paul Arora, CEO of Fifty1 Labs. "By combining our AI-driven drug repurposing capabilities with LUNR's pl...